Skip to main content
You have permission to edit this article.
Six Arizona Bioscience Firms Selected for Flinn Foundation Entrepreneurship Program

Six Arizona Bioscience Firms Selected for Flinn Foundation Entrepreneurship Program

  • Updated

PHOENIX--(BUSINESS WIRE)--#Arizona--Six Arizona bioscience startup firms have been competitively selected by

the Flinn Foundation to participate in its 2018 Bioscience

Entrepreneurship Program, receiving $30,000 each in funding support and

program services administered through a nonprofit partner.

The Phoenix-based Flinn Foundation has allocated $825,000 in grants

since 2014 to nonprofits to administer funding and services to 28

bioscience startups. The foundation’s program was established to foster

entrepreneurship and help early-stage bioscience companies develop into

successful and sustainable businesses in Arizona.

“The six companies chosen this year are further evidence of the amazing

innovation that is occurring in the biosciences here in Arizona,” said

Tammy McLeod, Flinn Foundation President and CEO. “The leaders of these

companies demonstrate both the talent and entrepreneurial spirit to

bring new technologies to market that will improve and save lives.”

The firms were selected from 30 applicants, a record for the program.

The 2018 winning companies, based in Mesa, Phoenix, Scottsdale and

Tucson, are:

Avery Therapeutics (


Therapeutics is a Tucson-based startup company dedicated to

advancing tissue-engineered therapeutics to treat diseases and injuries

to human muscle. Avery’s lead product, MyCardia, a tissue-engineered

heart graft developed to treat heart failure, is in the pre-clinical

development phase. MyCardia is positioned to be the world’s first

off-the-shelf product for treating heart failure.

Gemneo Bioscience (


Gemneo Bioscience has created a new immune-cell profiling technology

that identifies each patient’s unique tumor signature and also

identifies rogue cells that current technologies have not been able to

detect. The technology will give physicians a more precise tool for

effectively treating cancer and a host of other diseases.

GT Medical Technologies (


Medical Technologies, a Mesa-based medical device company, has developed

an innovative approach to the treatment of brain tumors by combining a

conformable collagen matrix with brachytherapy (radiation) seeds. The

company's first product, GammaTile, is protected by 10 issued U.S.

patents and is available for investigative uses.

TheraSpecs (


TheraSpecs manufactures and sells precision-tinted eyewear that helps

people with more than 50 conditions, including migraines, multiple

sclerosis, epilepsy, autism spectrum disorders and traumatic brain

injuries. The lenses directly address light-triggering symptoms from

fluorescent lighting, computer and device screens, or sunlight for those

with conditions triggered or worsened by light.

TouchPoint Solution (


Scottsdale-based company’s flagship product, TouchPoints, is a

neuroscience wearable that alleviates stress in as little as 30 seconds.

A successful PTSD therapy component isolated into the patent-pending

BLAST technology can reduce general stress, improve sleep and focus,

enhance performance, reduce cravings, and help users manage anger by

safely and non-invasively interfering with nervous system reactivity.

Vapometry Biolabs (


Biolabs of Phoenix analyzes the gases released by biological specimens

to create accurate, cost-effective diagnostics for hospitals and

consumers. The company's flagship product is a diagnostic for sepsis,

which affects over 1 million Americans every year, that diagnoses the

disease within four hours—a four-to-tenfold improvement over the current

standard of care.

In addition to funding and services, company leaders will participate

for one year as members of Arizona’s

Bioscience Roadmap Steering Committee, a group of the state’s

science, health care, business, academia and policy leaders that guides

Arizona’s Bioscience Roadmap.

To qualify for the Flinn program, the selected firms must be engaged in

the commercialization of bioscience research and biotechnology, and/or

the sale of products in the areas of medical devices and equipment;

drugs, pharmaceuticals and diagnostics; agricultural feedstock and

chemicals; research, testing and medical labs; or bioscience-related

distribution—the industry categories recognized together as the

biosciences in Arizona’s

Bioscience Roadmap.

The application for the 2019 Flinn Foundation Bioscience

Entrepreneurship Program will be available later this year. To learn

more about the program and past winners, visit

The Flinn Foundation is a privately endowed, philanthropic grantmaking

organization established in 1965 by Dr. Robert S. and Irene P. Flinn to

improve the quality of life in Arizona to benefit future generations. In

addition to advancing the biosciences, the foundation supports the Flinn

Scholars Program, a merit-based college scholarship program; arts and

culture; and the Arizona Center for Civic Leadership.


Flinn Foundation

Brian Powell, 602-744-6806



Ellsworth, 602-744-6813

Subscribe to stay connected to Tucson. A subscription helps you access more of the local stories that keep you connected to the community.

The business news you need

* I understand and agree that registration on or use of this site constitutes agreement to its user agreement and privacy policy.

Related to this story

Most Popular

Get up-to-the-minute news sent straight to your device.


News Alerts

Breaking News